TRANSCODE THERAPEUTICS INC (RNAZ) Stock Overview
USA - NASDAQ:RNAZ - US89357L5012 - Common Stock
RNAZ Key Statistics, Chart & Performance
The current stock price of RNAZ is 10.95 USD. In the past month the price increased by 3.5%. In the past year, price decreased by -97.53%.
RNAZ Latest News, Press Relases and Analysis
RNAZ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.13B | ||
| AMGN | AMGEN INC | 13.39 | 157.20B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 146.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.79 | 107.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.53 | 69.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.93B | ||
| ARGX | ARGENX SE - ADR | 89.07 | 50.51B | ||
| INSM | INSMED INC | N/A | 41.05B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.96 | 33.85B | ||
| NTRA | NATERA INC | N/A | 26.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| BIIB | BIOGEN INC | 9.34 | 21.93B |
Related stock screener links
About RNAZ
Company Profile
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-04-28. The company is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The firm is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Company Info
TRANSCODE THERAPEUTICS INC
6 Liberty Square, #2382
Boston MASSACHUSETTS US
CEO: Robert Michael Dudley
Employees: 7
Phone: 18573016857
TRANSCODE THERAPEUTICS INC / RNAZ FAQ
What does TRANSCODE THERAPEUTICS INC do?
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-04-28. The company is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The firm is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
What is the stock price of TRANSCODE THERAPEUTICS INC today?
The current stock price of RNAZ is 10.95 USD. The price decreased by -8.21% in the last trading session.
Does RNAZ stock pay dividends?
RNAZ does not pay a dividend.
What is the ChartMill technical and fundamental rating of RNAZ stock?
RNAZ has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is TRANSCODE THERAPEUTICS INC (RNAZ) stock traded?
RNAZ stock is listed on the Nasdaq exchange.
How is the valuation of TRANSCODE THERAPEUTICS INC (RNAZ) based on its PE ratio?
TRANSCODE THERAPEUTICS INC (RNAZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1462.72).
Can you provide the number of employees for TRANSCODE THERAPEUTICS INC?
TRANSCODE THERAPEUTICS INC (RNAZ) currently has 7 employees.
RNAZ Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to RNAZ. When comparing the yearly performance of all stocks, RNAZ is a bad performer in the overall market: 97.1% of all stocks are doing better.
RNAZ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RNAZ. While RNAZ seems to be doing ok healthwise, there are quite some concerns on its profitability.
RNAZ Financial Highlights
Over the last trailing twelve months RNAZ reported a non-GAAP Earnings per Share(EPS) of -1462.72. The EPS increased by 99.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -297.95% | ||
| ROE | -400.64% | ||
| Debt/Equity | 0 |
RNAZ Forecast & Estimates
For the next year, analysts expect an EPS growth of 99.7% and a revenue growth -100% for RNAZ